Page 3 - First Occurrence News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Message : Required fields Study quantified coronary plaque changes in patients administered 4 g/day of VASCEPA® (icosapent ethyl) on top of statin therapy Effect on coronary plaque stabilization reported to be significant at 9 months and sustained at 18 months DUBLIN, Ireland and BRIDGEWATER, N.J., April 17, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that further analyses from the Effect of Icosapent Ethyl on Progression of Coronary Atherosclerosis in Patients with Elevated Triglycerides on Statin Therapy: EVAPORATE Trial were presented as Late-Breaking ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. VASCEPA® (Icosapent Ethyl) Found in Prespecified and Post Hoc Analyses to Significantly Reduce ... Amarin Corporation plcMarch 17, 2021 GMT 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke obser...

Share: 28% and 32% significant reductions in first and total strokes, respectively, demonstrated with VASCEPA compared to placebo, as well as reductions in first and total ischemic strokes each by 36%, without increasing hemorrhagic stroke, in statin-treated patients with elevated cardiovascular risk Consistent reductions in overall stroke and in ischemic stroke observed across multiple subgroups Administration of pure icosapent ethyl, VASCEPA, represents a novel clinical approach to stroke reduction REDUCE-IT® STROKE abstract receives prestigious Paul Dudley White International Scholar Awa...

Press release content from Globe Newswire. The AP news staff was not involved in its creation. Amarin Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update Amarin Corporation plcFebruary 25, 2021 GMT Record Revenue of $614.1 Million and $167.3 Million for Full Year and Fourth Quarter 2020 Despite COVID-19 Impact Received Positive CHMP Opinion for VAZKEPA ® in Europe and Continue to Advance Commercial Launch Plans for Europe Management to Host Conference Call Today at 7:30 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Amar...

DUBLIN, Ireland and BRIDGEWATER, N.J., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN), announced today an expansion of the scope of ...